Evidence map›Paper›PMID 40699674›Full record

ArticleCurrent issues in molecular biology2025

A New Method for Preparation of Decellularized Human Scaffolds for Facial Reconstruction.

Elise Lupon, Aylin Acun, Alec R Andrews, Ruben Oganesyan, Hyshem H Lancia, Laurent Lantieri, Mark A Randolph, Curtis L Cetrulo, Alexandre G Lellouch, Basak E Uygun

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elise LuponDepartment of Plastic and Reconstructive Surgery, Institut Universitaire Locomoteur et du Sport, Pasteur 2 Hospital, University Côte d'Azur, 06107 Nice, France.ORCID 0000-0001-9414-0861
Aylin AcunShriners Children's Boston, Boston, MA 02114, USA.
Alec R AndrewsVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Ruben OganesyanShriners Children's Boston, Boston, MA 02114, USA.ORCID 0000-0001-8967-5597
Hyshem H LanciaVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Laurent LantieriService de Chirurgie Plastique et Reconstructrice, Hôpital Européen Georges-Pompidou, 75015 Paris, France.
Mark A RandolphVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
Curtis L CetruloVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-7080-3894
Alexandre G LellouchVascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8191-8662
Basak E UygunShriners Children's Boston, Boston, MA 02114, USA.

Funding

Development of engineered fasciocutaneous skin flapsR01AR082825 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Basak Elif Uygun · 2023 to 2026
$1.4M
NIAMS NIH HHS R01 AR082825NIH/NIAMS R01AR082825
6 · The paper itself

Abstract

Vascularized composite allotransplantation (VCA) has emerged as a robust alternative for addressing anatomically complex defects but requires a toxic lifelong immunosuppressive regimen. Tissue engineering offers the promise of creating recipient-specific alternative grafts using a decellularization and recellularization approach. In this article, we establish a reliable protocol for human face decellularization by immersion as a new tool in the development of engineered graft alternatives for reconstructive surgery. Three cadaveric face grafts were immersed in 1% sodium dodecyl sulfate for 216 h followed by 1% Triton X-100 for 48 h, without perfusion through the pedicle. We determined that decellularization was successfully accomplished for three facial specimens as confirmed by histological evaluation and quantification of DNA content. The extracellular components including collagen, glycosaminoglycans, elastin, and matrix-bound growth factors were preserved. Vascular architecture did not show significant differences between native and decellularized grafts as imaged by X-ray angiography. The mechanical strength of the grafts was not altered after decellularization. We also showed that the decellularized grafts were biocompatible in vitro and in vivo allowing cell engraftment. As a result, we have successfully developed a protocol to yield a clinical size decellularized graft suitable for generating a recellularized, potentially non-immunogenic graft for facial reconstruction.

Indexed as

decellularizationfacial reconstructionrecellularizationregenerative medicinescaffoldtissue engineeringvascularized composite allotransplantation

Identifiers

PMID40699674
PMCPMC12026321

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.